353 related articles for article (PubMed ID: 38111536)
21. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
22. The potential role and application of PARP inhibitors in cancer treatment.
Chalmers AJ
Br Med Bull; 2009; 89():23-40. PubMed ID: 19208614
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Drew Y; Plummer R
Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
[TBL] [Abstract][Full Text] [Related]
24. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.
Veuger SJ; Curtin NJ; Smith GC; Durkacz BW
Oncogene; 2004 Sep; 23(44):7322-9. PubMed ID: 15286704
[TBL] [Abstract][Full Text] [Related]
25. Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.
Thein KZ; Thawani R; Kummar S
Cancer Treat Res; 2023; 186():143-170. PubMed ID: 37978135
[TBL] [Abstract][Full Text] [Related]
26. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
27. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
28. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology.
Soldatenkov VA; Smulson M
Int J Cancer; 2000 Apr; 90(2):59-67. PubMed ID: 10814955
[TBL] [Abstract][Full Text] [Related]
30. Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion.
Hua HT; Albadawi H; Entabi F; Conrad M; Stoner MC; Meriam BT; Sroufe R; Houser S; Lamuraglia GM; Watkins MT
Arch Surg; 2005 Apr; 140(4):344-51; discussion 351-2. PubMed ID: 15837884
[TBL] [Abstract][Full Text] [Related]
31. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.
Huang RX; Zhou PK
Signal Transduct Target Ther; 2020 May; 5(1):60. PubMed ID: 32355263
[TBL] [Abstract][Full Text] [Related]
32. Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Mangoni M; Sottili M; Salvatore G; Campanacci D; Scoccianti G; Beltrami G; Delli Paoli C; Dominici L; Maragna V; Olmetto E; Meattini I; Desideri I; Bonomo P; Greto D; Livi L
Radiol Med; 2019 Apr; 124(4):282-289. PubMed ID: 29582320
[TBL] [Abstract][Full Text] [Related]
33. The potential of PARP inhibitors in neuro-oncology.
Carruthers R; Chalmers AJ
CNS Oncol; 2012 Sep; 1(1):85-97. PubMed ID: 25054302
[TBL] [Abstract][Full Text] [Related]
34. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) polymerase inhibitors as cancer therapy.
Hilton JF; Hadfield MJ; Tran MT; Shapiro GI
Front Biosci (Landmark Ed); 2013 Jun; 18(4):1392-406. PubMed ID: 23747892
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
37. Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.
Mitchell J; Smith GC; Curtin NJ
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1520-7. PubMed ID: 19931734
[TBL] [Abstract][Full Text] [Related]
38. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
40. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
